FABP1 and metabolic syndrome: Eradication therapy:Can partially reverse dyslipidemia.Is accompanied by the downregulation of key lipid regulatory genes (e.g., FABP1, MTP).Consistently increases HDL-C and apolipoprotein A1 (ApoA1) levels.